Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy
2021 ASTRO Annual Meeting
Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may benefit patients with localized prostate cancer. Further biomarkers are needed to better personalize treatment intensification (Abstract 8).
The ASCO Post Staff
Karen M. Winkfield, MD, PhD, of Vanderbilt University Medical Center, who co-chaired a session (PS 02) on digital health, summarizes the talks, which included ways to reduce disparities with digital innovations and the importance of patient input, especially in the form of patient-reported outcomes and experience measures. Advancing digital health, which the FDA defines as including health information technology, telemedicine, and personalized medicine, can potentially improve cancer care.
The ASCO Post Staff
Mark K. Buyyounouski, MD, MS, of Stanford University, discusses phase III results from the NRG Oncology GU003 trial, which showed that, post-prostatectomy, using fewer—but higher—doses of radiation does not appear to increase long-term side effects or reduce quality of life when compared with conventional radiation treatment (Abstract 3).
The ASCO Post Staff
Aadel A. Chaudhuri, MD, PhD, of Washington University School of Medicine in St. Louis, discusses circulating tumor DNA, which has the potential to better personalize treatment for patients with oligometastatic cancer and help clinicians determine whether to offer systemic therapy alone or curative-intent local consolidative therapy.
The ASCO Post Staff
Youssef Zeidan, MD, PhD, of Florida International University and the Lynn Cancer Institute, discusses the advances in radiotherapy planning and delivery that have reduced cardiac radiation exposure in patients with HER2-positive breast cancer who are treated with radiotherapy and trastuzumab (Abstract 12).
The ASCO Post Staff
Erin Murphy, MD, of Cleveland Clinic, discusses new data that show no apparent difference in cognitive performance up to 2 years post-treatment among adults with low-grade glioma who were treated with concurrent radiotherapy and temozolomide (Abstract 3258).